Yujuan Huang

Guangdong Academy of Medical Sciences and General Hospital, Shengcheng, Guangdong, China

Are you Yujuan Huang?

Claim your profile

Publications (10)21.13 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Erlotinib is a targeted treatment for advanced non-small cell lung cancer. Smoking status may be one of influencing factors of the efficacy of erlotinib. The aim of this study is to explore the impact of smoking status on the efficacy of erlotinib in patients with advanced non-small cell lung cancer. Patients with nonsmall cell lung cancer who had been previously treated with at least one course of platinum based chemotherapy received 150 mg oral doses of erlotinib once daily until disease progression. Response rate, progression-free survival, overall survival were analyzed in the different smoking status groups. Kaplan-Meier method was used to analyze the survival rate. Fortyeight patients were enrolled into the study from December 2005 to September 2006. We followed up these patients until 28th December, 2008. Median follow up time was 30 months. The compliance rate was 100%. The response rate was 32.1% in the smoking group and 35% in the never smoking group (P=0.836); The median progression-free survival was 3 months and 9 months, respectively (P=0.033). The median overall survival was 5 months and 17 months, respectively (P=0.162). Erlotinib is an effective drug for advanced non-small cell lung cancer patients with different smoking status. Progressionfree survival is better in the never smoking patients than the smoking patients.
    No preview · Article · Dec 2009 · Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: All the advanced NSCLC patients that received EGFR-TKI therapy will eventually relapse after a period of efficacy. The aim of this study is to investigate the serum biomarkers as potential predictive factors for the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in advanced non-small cell lung cancer. Twenty self-paired serum samples were collected from 9 advanced NSCLC patients that evaluated as disease control (SD or PR) after gefinitib therapy, at the time points of before and after gefinitib treatment but 2 weeks before being evaluated as disease progress. All samples were pre-separated by WCX microbeads, and then detected on the MALDI-TOF-MS platform of Bruker Autoflex. ClinProTools (Version: 2.1) was used to analyze the differentially expressed proteins. There were 7 protein peaks (m/z), 3 242.09, 8 690.36, 2 952.64, 3 224.04, 1 450.51, 1 887.8 and 3 935.73 found statistically differentially expressed between the self-paired samples. Three proteins (3 242.09, 2 952.64 and 3 224.04) were down-regulated and four proteins (8 690.36, 1 450.51, 1 887.8 and 3 935.73) up-regulated in gefinitib treated sera. The data here suggest that several specific protein peaks might indicate gefinitib resistance, yet the identities of these proteins and the mechanisms underlying the responsiveness to gefinitib treatment need further investigation.
    Full-text · Article · Jul 2009 · Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Erlotinib is a targeted drug for non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the efficacy, influencing factors and toxicity of erlotinib in patients with NSCLC. Patients with NSCLC who had been previously treated with at least one course of platinum based chemotherapy received 150 mg oral doses of erlotinib once daily until disease progression. Response rate, progression free survival, overall survival and toxicity profile were analyzed. Kaplan-Meier methods was used to analyze the survival rate. Cox regression was used to define the predictive factors. Forty-eight patients were enrolled into the study from Dec, 2005 to Sep, 2006. We followed up these patients until 08.Dec.2008. Median follow up time was 30 months. The compliance rate was 100%. The median symptom improving time was 7 days. Partial response 33.4% (16/48), stable disease 22.9% (11/48), and progressive disease 43.7% (21/48). Response rate was 33.4% (16/48). Disease control rate was 56.3% (27/48). One and two-year progression-free survival rates and overall survival rates were 25%(events 36), 8.3% (events 40) and 43.8% (death 27), 20.8% (death 38); three-year overall survival 5.6%. The median progression-free survival time and median overall survival time was 5 months and 8 months, respectively. Performance status was the only predictor for overall survival in the Cox model (P <0.001). Skin toxicity (grade 1 to 3) was found in 93.7% patients. One patient discontinued erlotinib because of perianal abscess. Erlotinib is another effective drug for patients with previously chemotherapy advanced NSCLC and accepted toxicity profile.
    No preview · Article · May 2009 · Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • Yilong Wu · Jinji Yang · Yujuan Huang · Qin Zhou · Yisheng Huang · Chongrui Xu
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective We conducted a prospective phase II trial of single-agent salvage chemotherapy with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy and gefitinib to assess the efficacy and toxicity of docetaxel in this setting. Methods Patients with histologically confirmed NSCLC who were failure of chemotherapy and gefitinib were given docetaxel 75 mg/m2 intravenously for 30 min every 3 weeks until the toxicity was unacceptable or disease progressed. The response evaluation criteria in solid tumors (RECIST) guidelines were used for the evaluation of antitumor activity. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 2.0. Results In total, 31 patients were enrolled in this phase II trial between February 2004 and December 2006, and 84 cycles (average 2.7 cycles) were given. We observed 4 partial responses (PRs) and 10 stable disease (SD) states in 31 eligible patients. The objective response rate was 12.9%, and the disease control rate was 45.2%. The median survival time (MST) was 10 months (95% CI, 5.05–15.08 months). The 1-year survival rate was 40.6%. The most common toxicities were neutropenia, anemia, and peripheral neuropathy that occurred as follows: 45% of the patients experienced grade 3 or 4 neutropenia, 29% experienced grade 3 anemia, and 25.8% had grade 3 peripheral neuropathy. No patient terminated docetaxel chemotherapy due to toxicity. Conclusion Docetaxel is beneficial as salvage chemotherapy in patients with advanced NSCLC after failure of cytotoxic agents and gefitinib.
    No preview · Article · Aug 2008 · The Chinese-German Journal of Clinical Oncology

  • No preview · Article · Aug 2007 · Journal of Thoracic Oncology

  • No preview · Article · Aug 2007 · Journal of Thoracic Oncology
  • Yisheng Huang · Yilong Wu · Yujuan Huang · Jinji Yang · Riqiang Liao

    No preview · Article · Aug 2007 · Journal of Thoracic Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Conventional treatment for non-small cell lung cancer (NSCLC) brain metastases (BM) is whole-brain radiotherapy (WBRT). The efficacy is limited. It might be increased by a potent radiosensitizer such as gemcitabine, which is believed to cross the disrupted blood-brain barrier. The primary objective of this study was to determine the maximum tolerated dose (MTD) of weekly gemcitabine given concurrently with WBRT. Methods: Patients with BM from NSCLC were included. The dose of WBRT was 3750 cGy (total 15 times, 3 weeks). Gemcitabine was given concurrently with WBRT on days 1, 8 and 15. The starting dose was 400 mg/m2, escalated by 100 mg/m2 increments. At least three patients were included per level. Dose limiting toxicity (DLT) was defined as grade 4 hematological or grade 2 neurological toxicity. When two or more patients experience DLT, the MTD was reached. Results: A total of 16 patients were included; 69% had a performance status (PS) 1 (Eastern Cooperative Oncology Group, ECOG). A total of 69% had concurrent active extra cranial diseases. All had more than 3 BM. Up to 600 mg/m2 (level 3) no neurology toxicity was observed. At 600 mg/ m2 two out of 9 patients developed grade 4 thrombocytopenia. One of the two patients' thrombocytopenia was confused with disseminated intravascular coagulation (DIC). At 700 mg/m2 two out of 4 patients developed neurotoxicities. One developed grade 3 seizure and cognitive disorder. Another patient developed suspected grade 2 muscle weakness. Conclusions: The MTD was reached at a dose of 700 mg/m2. The dose of 600 mg/m2 would be considered for further study.
    No preview · Article · Aug 2007 · Journal of Thoracic Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: RRM1 may be a prognostic factor in non-small cell lung cancer (NSCLC). The aim of this study is to evaluate RRM1 expression and prognosis in NSCLC by the means of tissue microarray. A total of 417 paraffin-embedded specimens of NSCLC from Lung Cancer Study Center in Guangdong Provincial People's Hospital were collected and tissue microarray was constructed. RRM1 expression was detected by SP method and its correlation with prognosis was evaluated. No statistic difference was found in RRM1 expression in different gender, age, tumor site, histology, differentiation, T stage, N stage, M stage and pTNM stage groups (P > 0.05). Univariate analysis showed that RRM1 was not an independent prognostic factor (P > 0.05). At the multivariate analysis, differentiation and N stage were considered independent prognostic factors. RRM1 expression detected by immunohistology is not an independent prognostic factor in NSCLC. TNM stage is still the best prognostic factor up to now.
    No preview · Article · Oct 2006 · Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • Yilong Wu · Xuening Yang · Jinji Yang · Yujuan Huang
    [Show abstract] [Hide abstract]
    ABSTRACT: To explore the experience of gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer (NSCLC). The unpublished data of gefitinib for advanced NSCLC in 7 hospitals were collected. The detailed data from Guangdong Provincial People's Hospital were analyzed. A total of 282 patients with advanced NSCLC was treated with gefitinib from July 2001 to December 2003. Response rate was 22.2%-47.7%, disease control rate 62.6%-81.8%. No severe side effects were surveyed. Gefitinib can be used safely and effectively in Chinese patients with advanced NSCLC.
    No preview · Article · Aug 2004 · Zhongguo fei ai za zhi = Chinese journal of lung cancer